AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1–14 (Canceled).

Claim 15 (Withdrawn): A method for disinfecting a liquid containing a Human Immunodeficiency Virus comprising adding to the liquid a composition comprising a Human Immunodeficiency Virus prophylactic effective amount of a compound having the structure



(II)

wherein each

A may be the same or different and is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;

Y may be the same or different and is hydrogen, an unbranched alkyl group, a halide or a group having the structure $R-\overset{\overset{O}{\|}}{C}-$ wherein R is hydrogen, an alkoxide group, an alkyl group, or OH;

B may be the same or different and each is hydrogen or an alkyl group;

Z^- is a soluble, pharmaceutically acceptable negative ion, and

X may be the same or different and is an axial ligand selected from the group consisting of moieties having the formula:



(IIa)

wherein R^1, R^2, R^3, and R^4 may be the same or different and may be hydrogen or lower alkyl having from 1 to 4 carbon atoms;

with the proviso that R^1, R^2, R^3, and R^4 are of a sufficiently small size so as not to prohibit the attachment of the axial ligand to the Co atom due to steric hindrance.

Claim 16 (Withdrawn): The method of claim 15 wherein the compound is added in an amount of about 0.00005 to about 5% by weight of the liquid.

Claim 17 (Withdrawn): The method of claim 15 wherein the compound is added in an amount of about 0.005 to about 5% by weight of the liquid.

Claim 18 (Withdrawn): The method of claim 15 wherein the compound is added in an amount of about 0.005 to about 2% by weight of the liquid.

Claim 19 (Withdrawn): The method of claim 15 wherein the compound is added in an amount of about 0.01 to about 2% by weight of the liquid.

Claim 20 (Withdrawn): The method of claim 15 wherein the liquid is a growth media or a blood-derived product.

Claim 21 (Withdrawn): A method for preventing Human Papillomavirus infection in a subject comprising topically applying to the subject a composition comprising a Human Papillomavirus prophylactic effective amount of a compound having the structure



(II)

wherein each

A may be the same or different and is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;

Y may be the same or different and is hydrogen, an unbranched alkyl group, a halide or a group having the structure 

wherein R is hydrogen, an alkoxide group, an alkyl group, or OH;

B may be the same or different and each is hydrogen or an alkyl group;

Z^- is a soluble, pharmaceutically acceptable negative ion, and

X may be the same or different and is an axial ligand selected from the group consisting of moieties having the formula:  (IIa)

wherein R^1, R^2, R^3, and R^4 may be the same or different and may be hydrogen or lower alkyl having from 1 to 4 carbon atoms;

with the proviso that R^1, R^2, R^3, and R^4 are of a sufficiently small size so as not to prohibit the attachment of the axial ligand to the Co atom due to steric hindrance.

Claim 22 (Withdrawn): The method of claim 21 wherein the compound is from about 0.00005 to about 5% by weight of the composition.

Claim 23 (Withdrawn): The method of claim 21 wherein the compound is from about 0.005 to about 5% by weight of the composition.

Claim 24 (Withdrawn): The method of claim 21 wherein the compound is from about 0.005 to about 2% by weight of the composition

Claim 25 (Withdrawn): The method of claim 21 wherein the compound is from about 0.01 to about 2% by weight of the composition.

Claim 26 (Withdrawn): The method of claim 21 wherein the composition is in the form of a pharmaceutically acceptable saline solution, ointment, salve, creme, or the like.

Claim 27 (Withdrawn): The method of claim 21 wherein the composition is applied to that site on the subject which is exposed to the Human Papillomavirus.

Claim 28 (Withdrawn): The method of claim 27 wherein the composition is applied intravaginally.

Claim 29 (Withdrawn): The method of claim 27 wherein the composition is applied from about 1 hour before to about 6 hours after exposure to the Human Papillomavirus.

Claim 30 (Withdrawn): The method of claim 27 wherein the composition is applied from about 5 minutes before to about 5 minutes after exposure to the Human Papillomavirus.

Claim 31 (Withdrawn): The method of claim 21 wherein the Human Papillomavirus is selected from the group consisting of HPV-1, HPV-2, HPV-3, HPV-4, HPV-6, HPV-7, HPV-10, HPV-11, HPV-16, HPV-18, HPV-31 or HPV-45.

Claim 32 (Withdrawn): The method of claim 21 wherein the compound is CTC 96.

Claim 33 (Withdrawn): The method of claim 21 wherein the step of topically applying the composition is performed by contacting the subject with an applicator coated with the composition.

Claim 34 (Withdrawn): The method of claim 33 wherein the applicator is a condom.

Claim 35 (Withdrawn): A method for disinfecting a liquid containing a Human Papillomavirus comprising adding to the liquid a composition comprising a Human Papillomavirus prophylactic effective amount of a compound having the structure:



(II)

wherein each

A may be the same or different and is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;

Y may be the same or different and is hydrogen, an unbranched alkyl group, a halide or a group having the structure $R-\overset{\overset{O}{\|}}{C}-$

wherein R is hydrogen, an alkoxide group, an alkyl group, or OH;

B may be the same or different and each is hydrogen or an alkyl group;

Z^- is a soluble, pharmaceutically acceptable negative ion, and

X may be the same or different and is an axial ligand selected from the group consisting of moieties having the formula:



(IIa)

wherein R^1, R^2, R^3, and R^4 may be the same or different and may be hydrogen or lower alkyl having from 1 to 4 carbon atoms; with the proviso that R^1, R^2, R^3, and R^4 are of a sufficiently small size so as not to prohibit the attachment of the axial ligand to the Co atom due to stearic hindrance.

Claim 36 (Withdrawn): The method of claim 35 wherein the compound is added in an amount of about 0.00005 to about 5% by weight of the liquid.

Claim 37 (Withdrawn): The method of claim 35 wherein the compound is added in an amount of about 0.005 to about 5% by weight of the liquid.

Claim 38 (Withdrawn): The method of claim 35 wherein the compound is added in an amount of about 0.005 to about 2% by weight of the liquid.

Claim 39 (Withdrawn): The method of claim 35 wherein the compound is added in an amount of about 0.01 to about 2% by weight of the liquid.

Claim 40 (Withdrawn): The method of claim 35 wherein the liquid is a growth media or a blood-derived product.

Claim 41 (Previously presented): A method for prophylactically reducing the risk of transmission of Human Immunodeficiency Virus infection to a recipient and protecting the recipient from infection with Human Immunodeficiency Virus infection comprising topically applying a Human Immunodeficiency Virus infection prophylactic effective amount to that site on the recipient which is subject to exposure to Human Immunodeficiency Virus infection a composition comprising a Human Immunodeficiency Virus infection prophylactic effective amount of a compound having the structure



wherein each

A is the same or different and is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;

Y is the same or different and is hydrogen, an unbranched alkyl group, a halide or a group having the structure $R-\overset{\overset{O}{\|}}{C}-$

wherein R is hydrogen, an alkoxide group, an alkyl group, or OH;

B is the same or different and each is hydrogen or an alkyl group;

Z^- is a soluble, pharmaceutically acceptable negative ion; and

X is the same or different and is an axial ligand selected from the group consisting of moieties having the formula:



(IIa)

wherein R^1, R^2, R^3, and R^4 are the same or different and may be hydrogen or lower alkyl having from 1 to 4 carbon atoms;

with the proviso that R^1, R^2, R^3, and R^4 are of a sufficiently small size so as not to prohibit the attachment of the axial ligand to the Co atom due to steric hindrance.

Claim 42 (Previously presented): The method of claim 41 wherein the compound is from about 0.00005 to about 5% by weight of the composition.

Claim 43 (Previously presented): The method of claim 41 wherein the compound is from about 0.005 to about 5% by weight of the composition.

Claim 44 (Previously presented): The method of claim 41 wherein the compound is from about 0.005 to about 2% by weight of the composition.

Claim 45 (Previously presented): The method of claim 41 wherein the compound is from about 0.01 to about 2% by weight of the composition.

Claim 46 (Previously presented): The method of claim 41 wherein the composition is in the form of a pharmaceutically acceptable saline solution, ointment, salve or crème.

Claim 47 (Previously presented): The method of claim 41 wherein the composition is applied intravaginally.

Claim 48 (Previously presented): The method of claim 41 wherein the composition is applied from about 1 hour before to about 6 hours after the exposure to the Human Immunodeficiency Virus.

Claim 49 (Previously presented): The method of claim 41 wherein the composition is applied from about 5 minutes before to about 5 minutes after exposure to the Human Immunodeficiency Virus.

Claim 50 (Previously presented): The method of claim 41 wherein the Human Immunodeficiency Virus is HIV-1 or HIV-2.

Claim 51 (Previously presented): The method of claim 41 wherein the compound is compound 96.

Claim 52 (Previously presented): The method of claim 41 wherein the step of topically applying the composition is performed by contacting the subject with an applicator coated with the composition.

Claim 53 (Previously presented): The method of claim 52 wherein the applicator is a condom.

If the Examiner believes that additional issues need to be resolved before this application can be passed to issue, the undersigned invites the Examiner to contact him at the telephone number provided below.

Respectfully submitted,

Dated: June 27, 2005

By _____

Jules. E. Goldberg
Reg. No. 24,408
REED SMITH LLP
599 Lexington Avenue
29th Floor
New York, NY 10022-7650
(212) 521-5400
Attorney for Applicant